Related Experiment Videos
Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing.
Tawee Tanvetyanon1, Sucha Nand
1Division of Hematology/Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL, USA. ttanve@lumc.edu
The Annals of Pharmacotherapy
|November 25, 2003
Summary
Once-weekly imatinib is a safe and effective strategy for patients experiencing severe skin reactions during treatment for acute lymphoblastic leukemia. This modified dosing schedule helped a patient tolerate imatinib, leading to reaction resolution.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Imatinib is a tyrosine kinase inhibitor used in cancer therapy.
- Cutaneous reactions are a known side effect of imatinib treatment.
- Severe reactions can necessitate treatment discontinuation.
Observation:
- A patient with acute lymphoblastic leukemia developed exfoliative dermatitis after initiating imatinib therapy.
- Lowering the imatinib dose and adding corticosteroids did not prevent recurrent skin reactions.
- A switch to once-weekly imatinib administration resulted in a less severe, tolerable reaction.
Findings:
- Once-weekly imatinib administration was safe and well-tolerated in this patient.
- The modified dosing schedule allowed for continued imatinib therapy.
- The patient's exfoliative dermatitis eventually subsided and disappeared with the weekly regimen.
Implications:
- Once-weekly imatinib may be a viable option for patients with severe cutaneous reactions requiring continued treatment.
- This strategy, potentially combined with dose reduction and corticosteroid premedication, could improve treatment adherence and outcomes.
- Further investigation into modified imatinib dosing for managing adverse cutaneous events is warranted.